Literature DB >> 22609878

Treatment options for malignant pleural effusions: patient preference does matter.

Nick A Maskell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22609878     DOI： 10.1001/jama.2012.5543

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Tunneled pleural catheter use for pleural palliation does not increase infection rate in patients with treatment-related immunosuppression.

Authors:  Candice L Wilshire; Christopher R Gilbert; Brian E Louie; Ralph W Aye; Alexander S Farivar; Eric Vallières; Jed A Gorden
Journal:  Support Care Cancer       Date:  2017-11-29       Impact factor: 3.603

2.  Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial.

Authors:  Rajesh Thomas; Edward T H Fysh; Nicola A Smith; Pyng Lee; Benjamin C H Kwan; Elaine Yap; Fiona C Horwood; Francesco Piccolo; David C L Lam; Luke A Garske; Ranjan Shrestha; Christopher Kosky; Catherine A Read; Kevin Murray; Y C Gary Lee
Journal:  JAMA       Date:  2017-11-21       Impact factor: 56.272

Review 3.  Current best practice in the evaluation and management of malignant pleural effusions.

Authors:  Steven Walker; Anna C Bibby; Nick A Maskell
Journal:  Ther Adv Respir Dis       Date:  2016-10-24       Impact factor: 4.031

4.  Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters.

Authors:  David E Ost; Carlos A Jimenez; Xiudong Lei; Scott B Cantor; Horiana B Grosu; Donald R Lazarus; Saadia A Faiz; Lara Bashoura; Vickie R Shannon; Dave Balachandran; Lailla Noor; Yousra B Hashmi; Roberto F Casal; Rodolfo C Morice; George A Eapen
Journal:  Chest       Date:  2014-06       Impact factor: 9.410

5.  Successful use of central venous catheters in the management of recurrent malignant pleural effusions: one new option.

Authors:  Abbas Yazdanbod; Azita Salehifar; Nasrollah Maleki; Shahram Habibzadeh; Zahra Tavosi
Journal:  Support Care Cancer       Date:  2015-01-10       Impact factor: 3.603

6.  Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis.

Authors:  Srinivas Mummadi; Anusha Kumbam; Peter Y Hahn
Journal:  F1000Res       Date:  2014-10-27

7.  Immune Regulation of Interleukin-27 in Malignant Pleural Effusion.

Authors:  Shi Li; Wen-Jie You; Jian-Chu Zhang; Qiong Zhou; Huan-Zhong Shi
Journal:  Chin Med J (Engl)       Date:  2015-07-20       Impact factor: 2.628

8.  Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.

Authors:  Antonia Marazioti; Chrysoula A Kairi; Magda Spella; Anastasios D Giannou; Sophia Magkouta; Ioanna Giopanou; Vassilios Papaleonidopoulos; Ioannis Kalomenidis; Linda A Snyder; Dimitrios Kardamakis; Georgios T Stathopoulos
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

9.  Monoclonal antibody targeting of mononuclear cell chemokines driving malignant pleural effusion.

Authors:  Antonia Marazioti; Georgios T Stathopoulos
Journal:  Oncoimmunology       Date:  2014-06-11       Impact factor: 8.110
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.